Loin Pain Hematuria Syndrome Sidelines an Active 28-Year-Old
https://pixabay.com/en/people-woman-travel-adventure-trek-2591874/

Loin Pain Hematuria Syndrome Sidelines an Active 28-Year-Old

The active and adventurous Devaney Mehl was sidelined by excruciating pain when only 28-years-old, originally reported in Regina Leader-Post. After many incorrect diagnoses, she later learned she had developed the rare…

Continue Reading Loin Pain Hematuria Syndrome Sidelines an Active 28-Year-Old
Cannabidiol Oral Solution Granted Fast Track Application for Prader-Willi Syndrome
Source: Pixabay

Cannabidiol Oral Solution Granted Fast Track Application for Prader-Willi Syndrome

Prader-Willi syndrome is a rare condition which causes the body to feel insatiable hunger, regardless of how much a patient eats. Treatment options are currently inadequate for many patients. Today,…

Continue Reading Cannabidiol Oral Solution Granted Fast Track Application for Prader-Willi Syndrome
Recent Study Results Reveal New Possibilities in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH causes the immune system to destroy red blood cells. Source: pixabay.com

Recent Study Results Reveal New Possibilities in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)

On December 11, Alexion Pharmaceuticals, Inc. released dose-ranging data from a recent clinical study involving treatment with ALXN1210, which is an investigational long-acting C5 complement inhibitor meant to treat sufferers…

Continue Reading Recent Study Results Reveal New Possibilities in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety
Source: Pixabay

Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety

Caplacizumab is a medicine that has been developed to treat acquired thrombotic thrombocytopenic purpura (TTP). TTP causes serious symptoms. such as thrombocytopenia, a condition in which a patient doesn't have enough platelets. A…

Continue Reading Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety
Study of LJPC-401 Treatment for Hereditary Hemochromatosis Launches into Phase II
Source: Pixabay

Study of LJPC-401 Treatment for Hereditary Hemochromatosis Launches into Phase II

Hereditary hemochromatosis is a genetic form of a condition in which the body builds up too much iron. To read more about hemochromatosis, click here. La Jolla Pharmaceutical Company has…

Continue Reading Study of LJPC-401 Treatment for Hereditary Hemochromatosis Launches into Phase II